Ximelagatran for stroke prevention in atrial fibrillation

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Atrial fibrillation is the most common cardiac arrhythmia and a leading cause of embolic stroke.
• Vitamin K antagonists like warfarin are standard anticoagulants but have limitations including underuse and monitoring requirements.
• There is a significant clinical need for safer, more practical oral anticoagulants for atrial fibrillation.

Purpose of the Study:

• To evaluate the efficacy and safety of ximelagatran, a novel oral direct thrombin inhibitor, as an alternative anticoagulant for patients with nonvalvular atrial fibrillation.
• To compare the stroke and embolic event prevention capabilities of ximelagatran against warfarin.

Main Methods:

• The Stroke Prevention using the ORal Thrombin Inhibitor in patients with nonvalvular atrial Fibrillation (SPORTIF) III and V trials were conducted.
• These trials compared the efficacy of ximelagatran (fixed twice-daily dose, no monitoring required) with warfarin in patients with atrial fibrillation.

Main Results:

• The SPORTIF III and V trials demonstrated that ximelagatran is non-inferior to warfarin in preventing stroke and embolic events.
• Ximelagatran offers potential advantages such as a low drug interaction profile and no need for routine anticoagulation monitoring.
• Safety concerns have arisen due to ximelagatran's propensity to cause elevated liver enzymes.

Conclusions:

• Ximelagatran represents a promising alternative oral anticoagulant for atrial fibrillation, demonstrating comparable efficacy to warfarin.
• The clinical utility of ximelagatran may be constrained by its safety profile, specifically its association with hepatotoxicity.
• Further research and careful patient selection are warranted to balance the benefits and risks of ximelagatran therapy.